|
2024-03-05 |
2024-03-04 |
S
Sale
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Officer
|
840
-0.5%
16.01
13,448
USD
|
840
-0.5%
|
16.01
|
13,448
USD
|
|
|
2024-03-05 |
2024-03-04 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
1,217
-0.5%
16.01
19,484
USD
|
1,217
-0.5%
|
16.01
|
19,484
USD
|
|
|
2024-03-05 |
2024-03-01 |
S
Sale
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Officer
|
1,679
-1.0%
16.03
26,909
USD
|
1,679
-1.0%
|
16.03
|
26,909
USD
|
|
|
2024-03-05 |
2024-03-01 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
2,107
-0.8%
16.03
33,769
USD
|
2,107
-0.8%
|
16.03
|
33,769
USD
|
|
|
2024-02-29 |
2024-02-28 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
2,303
-0.9%
16.14
37,177
USD
|
2,303
-0.9%
|
16.14
|
37,177
USD
|
|
|
2024-02-29 |
2024-02-28 |
S
Sale
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Officer
|
2,078
-1.3%
16.14
33,545
USD
|
2,078
-1.3%
|
16.14
|
33,545
USD
|
|
|
2023-11-08 |
2023-11-07 |
PS
Planned sale
|
Shah Pritesh
Chief Growth Officer
Officer
|
382
-0.3%
12.65
4,832
USD
|
382
-0.3%
|
12.65
|
4,832
USD
|
|
|
2023-09-05 |
2023-09-01 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
294
-0.1%
21.82
6,414
USD
|
294
-0.1%
|
21.82
|
6,414
USD
|
|
|
2023-09-05 |
2023-09-01 |
S
Sale
|
Shah Pritesh
Chief Growth Officer
Officer
|
273
-0.2%
21.82
5,956
USD
|
273
-0.2%
|
21.82
|
5,956
USD
|
|
|
2023-09-05 |
2023-09-01 |
S
Sale
|
Cordova Ashley
Chief Financial Officer
Officer
|
883
-0.9%
21.82
19,265
USD
|
883
-0.9%
|
21.82
|
19,265
USD
|
|
|
2023-08-04 |
2023-08-02 |
S
Sale
|
Cordova Ashley
Chief Financial Officer
Officer
|
1,144
-1.1%
30.25
34,607
USD
|
1,144
-1.1%
|
30.25
|
34,607
USD
|
|
|
2023-03-07 |
2023-03-07 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
2,315
-4.1%
75.59
174,999
USD
|
2,315
-4.1%
|
75.59
|
174,999
USD
|
|
|
2023-03-07 |
2023-03-07 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
6,003
-9.6%
75.00
450,206
USD
|
6,003
-9.6%
|
75.00
|
450,206
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
20,415
-8.9%
76.16
1,554,794
USD
|
20,415
-8.9%
|
76.16
|
1,554,794
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
1,692
-0.7%
76.16
128,862
USD
|
1,692
-0.7%
|
76.16
|
128,862
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
3,528
-1.5%
76.16
268,690
USD
|
3,528
-1.5%
|
76.16
|
268,690
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Shah Pritesh
Chief Growth Officer
Officer
|
16,909
-11.9%
76.16
1,287,779
USD
|
16,909
-11.9%
|
76.16
|
1,287,779
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Shah Pritesh
Chief Growth Officer
Officer
|
2,942
-2.0%
76.16
224,061
USD
|
2,942
-2.0%
|
76.16
|
224,061
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Shah Pritesh
Chief Growth Officer
Officer
|
1,570
-1.1%
76.16
119,570
USD
|
1,570
-1.1%
|
76.16
|
119,570
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Burke William Patrick
Chief Human Resources Officer
Officer
|
593
-0.9%
76.16
45,163
USD
|
593
-0.9%
|
76.16
|
45,163
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Cordova Ashley
Chief Financial Officer
Officer
|
775
-0.8%
76.16
59,024
USD
|
775
-0.8%
|
76.16
|
59,024
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Cordova Ashley
Chief Financial Officer
Officer
|
4,730
-4.4%
76.16
360,234
USD
|
4,730
-4.4%
|
76.16
|
360,234
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
888
-1.4%
76.16
67,630
USD
|
888
-1.4%
|
76.16
|
67,630
USD
|
|
|
2023-03-07 |
2023-03-03 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
4,403
-6.5%
76.16
335,330
USD
|
4,403
-6.5%
|
76.16
|
335,330
USD
|
|
|
2023-03-06 |
2023-03-03 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
2,059
-2.9%
77.64
159,859
USD
|
2,059
-2.9%
|
77.64
|
159,859
USD
|
|
|
2023-03-06 |
2023-03-02 |
S
Sale
|
Burke William Patrick
Chief Human Resources Officer
Officer
|
281
-0.4%
75.28
21,153
USD
|
281
-0.4%
|
75.28
|
21,153
USD
|
|
|
2023-03-06 |
2023-03-02 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
1,213
-0.7%
75.28
91,312
USD
|
1,213
-0.7%
|
75.28
|
91,312
USD
|
|
|
2023-03-06 |
2023-03-02 |
S
Sale
|
Cordova Ashley
Chief Financial Officer
Officer
|
1,055
-1.1%
75.28
79,418
USD
|
1,055
-1.1%
|
75.28
|
79,418
USD
|
|
|
2023-03-06 |
2023-03-02 |
S
Sale
|
Shah Pritesh
Chief Growth Officer
Officer
|
937
-0.9%
75.28
70,535
USD
|
937
-0.9%
|
75.28
|
70,535
USD
|
|
|
2023-03-06 |
2023-03-02 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
844
-1.4%
75.28
63,535
USD
|
844
-1.4%
|
75.28
|
63,535
USD
|
|
|
2023-03-03 |
2023-03-02 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
308
-0.5%
76.05
23,424
USD
|
308
-0.5%
|
76.05
|
23,424
USD
|
|
|
2023-03-03 |
2023-03-02 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
3,799
-6.0%
75.32
286,154
USD
|
3,799
-6.0%
|
75.32
|
286,154
USD
|
|
|
2023-03-02 |
2023-03-01 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
2,164
-1.2%
76.36
165,248
USD
|
2,164
-1.2%
|
76.36
|
165,248
USD
|
|
|
2023-03-02 |
2023-03-01 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
1,684
-2.6%
76.36
128,594
USD
|
1,684
-2.6%
|
76.36
|
128,594
USD
|
|
|
2023-03-02 |
2023-03-01 |
S
Sale
|
Shah Pritesh
Chief Growth Officer
Officer
|
1,923
-1.9%
76.36
146,845
USD
|
1,923
-1.9%
|
76.36
|
146,845
USD
|
|
|
2023-03-02 |
2023-03-01 |
S
Sale
|
Cordova Ashley
Chief Financial Officer
Officer
|
2,198
-2.2%
76.36
167,845
USD
|
2,198
-2.2%
|
76.36
|
167,845
USD
|
|
|
2023-03-02 |
2023-03-01 |
S
Sale
|
Burke William Patrick
Chief Human Resources Officer
Officer
|
755
-1.1%
76.36
57,654
USD
|
755
-1.1%
|
76.36
|
57,654
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
7,183
-13.5%
120.00
861,960
USD
|
7,183
-13.5%
|
120.00
|
861,960
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
7,183
-13.5%
114.00
818,863
USD
|
7,183
-13.5%
|
114.00
|
818,863
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
5,517
-10.7%
108.00
595,836
USD
|
5,517
-10.7%
|
108.00
|
595,836
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
7,500
-14.0%
108.00
810,000
USD
|
7,500
-14.0%
|
108.00
|
810,000
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
7,826
-14.5%
108.00
845,208
USD
|
7,826
-14.5%
|
108.00
|
845,208
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
1,010
-2.1%
117.00
118,170
USD
|
1,010
-2.1%
|
117.00
|
118,170
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
526
-1.1%
115.03
60,508
USD
|
526
-1.1%
|
115.03
|
60,508
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
417
-0.9%
108.00
45,036
USD
|
417
-0.9%
|
108.00
|
45,036
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
2,345
-4.6%
119.01
279,073
USD
|
2,345
-4.6%
|
119.01
|
279,073
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Weinberg Uri
Chief Science Officer
Officer
|
1,201
-2.7%
120.00
144,120
USD
|
1,201
-2.7%
|
120.00
|
144,120
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Weinberg Uri
Chief Science Officer
Officer
|
2,617
-5.6%
108.00
282,636
USD
|
2,617
-5.6%
|
108.00
|
282,636
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Weinberg Uri
Chief Science Officer
Officer
|
1,946
-4.0%
120.00
233,520
USD
|
1,946
-4.0%
|
120.00
|
233,520
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Weinberg Uri
Chief Science Officer
Officer
|
2,379
-4.8%
120.00
285,480
USD
|
2,379
-4.8%
|
120.00
|
285,480
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
187,500
-93.2%
108.00
20,250,000
USD
|
187,500
-93.2%
|
108.00
|
20,250,000
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
500
-3.6%
119.99
59,994
USD
|
500
-3.6%
|
119.99
|
59,994
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
1,344
-8.7%
119.35
160,405
USD
|
1,344
-8.7%
|
119.35
|
160,405
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
2,123
-12.1%
118.47
251,515
USD
|
2,123
-12.1%
|
118.47
|
251,515
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
999
-5.4%
117.01
116,894
USD
|
999
-5.4%
|
117.01
|
116,894
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
1,395
-7.0%
116.06
161,906
USD
|
1,395
-7.0%
|
116.06
|
161,906
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
3,702
-15.7%
115.21
426,512
USD
|
3,702
-15.7%
|
115.21
|
426,512
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
4,568
-16.2%
114.35
522,362
USD
|
4,568
-16.2%
|
114.35
|
522,362
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
2,000
-6.6%
112.86
225,726
USD
|
2,000
-6.6%
|
112.86
|
225,726
USD
|
|
|
2023-01-09 |
2023-01-05 |
PS
Planned sale
|
Danziger Asaf
Chief Executive Officer
Executive Director
|
8,369
-21.7%
111.23
930,916
USD
|
8,369
-21.7%
|
111.23
|
930,916
USD
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Shah Pritesh
Chief Commercial Officer
Officer
|
387
-0.5%
108.00
41,796
USD
|
387
-0.5%
|
108.00
|
41,796
USD
|
|
|
2022-10-17 |
2022-10-13 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
6,754
-13.4%
76.01
513,372
USD
|
6,754
-13.4%
|
76.01
|
513,372
USD
|
|
|
2022-10-07 |
2022-10-06 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
6,754
-11.8%
84.37
569,835
USD
|
6,754
-11.8%
|
84.37
|
569,835
USD
|
|
|
2022-09-26 |
2022-09-22 |
S
Sale
|
Leonard Frank X
President, CNS Cancers US
Officer
|
6,754
-9.6%
77.00
520,058
USD
|
6,754
-9.6%
|
77.00
|
520,058
USD
|
|
|
2022-09-19 |
2022-09-15 |
S
Sale
|
Leonard Frank X
Chief Development Officer
Officer
|
5,517
-7.2%
90.00
496,530
USD
|
5,517
-7.2%
|
90.00
|
496,530
USD
|
|
|
2022-09-19 |
2022-09-15 |
S
Sale
|
Leonard Frank X
Chief Development Officer
Officer
|
6,754
-8.1%
87.31
589,692
USD
|
6,754
-8.1%
|
87.31
|
589,692
USD
|
|
|
2022-09-12 |
2022-09-09 |
S
Sale
|
Leonard Frank X
Chief Development Officer
Officer
|
1,863
-2.2%
88.00
163,944
USD
|
1,863
-2.2%
|
88.00
|
163,944
USD
|
|
|
2022-09-07 |
2022-09-06 |
S
Sale
|
Leonard Frank X
Chief Development Officer
Officer
|
1,384
-1.6%
78.57
108,741
USD
|
1,384
-1.6%
|
78.57
|
108,741
USD
|
|
|
2022-09-06 |
2022-09-02 |
S
Sale
|
Shah Pritesh
Chief Commercial Officer
Officer
|
269
-0.3%
79.04
21,261
USD
|
269
-0.3%
|
79.04
|
21,261
USD
|
|
|
2022-09-06 |
2022-09-02 |
S
Sale
|
Burke William Patrick
Chief Human Resources Officer
Officer
|
718
-1.3%
79.04
56,749
USD
|
718
-1.3%
|
79.04
|
56,749
USD
|
|
|
2022-09-06 |
2022-09-02 |
S
Sale
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Officer
|
296
-0.2%
79.04
23,395
USD
|
296
-0.2%
|
79.04
|
23,395
USD
|
|
|
2022-09-06 |
2022-09-02 |
S
Sale
|
Cordova Ashley
Chief Financial Officer
Officer
|
885
-1.2%
79.04
69,948
USD
|
885
-1.2%
|
79.04
|
69,948
USD
|
|
|
2022-09-06 |
2022-09-02 |
S
Sale
|
Leonard Frank X
Chief Development Officer
Officer
|
584
-0.7%
79.04
46,158
USD
|
584
-0.7%
|
79.04
|
46,158
USD
|
|
|
2022-09-06 |
2022-09-01 |
S
Sale
|
Leonard Frank X
Chief Development Officer
Officer
|
48
-0.1%
78.96
3,790
USD
|
48
-0.1%
|
78.96
|
3,790
USD
|
|
|
2022-09-06 |
2022-09-01 |
S
Sale
|
Leonard Frank X
Chief Development Officer
Officer
|
438
-0.5%
78.14
34,225
USD
|
438
-0.5%
|
78.14
|
34,225
USD
|
|
